Compare iShares Core MSCI EAFE ETF (IEFA) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Core MSCI EAFE ETF vs Johnson & Johnson — how do they compare? iShares Core MSCI EAFE ETF trades at $101.08, while Johnson & Johnson trades at $260.6 (market cap $626.09B). The key difference: Johnson & Johnson pays a 2.06% dividend while iShares Core MSCI EAFE ETF pays none. Which is the better fit depends on your goals.
| IEFA | JNJ | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $101.09 | $267.24 |
52-Week Low | $84.72 | $174.16 |
Market Cap | — | $626.09B |
Volume | — | 6,156,228 |
Enterprise Value | — | $654.37B |
Dividend Yield | — | 2.06% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IEFA, the iShares Core MSCI EAFE ETF, trades at $101.02, up 0.49% today, with a bullish technical signal driven by strong moving average alignment. The ETF focuses on developed international equities outside the U.S. and Canada, offering diversification and a dividend yield of 3.30% (The Motley Fool, 2026-06-17). Recent news highlights its cost efficiency and income appeal compared to peers like EFA and VXUS.
The outlook remains positive due to international diversification benefits and potential Fed rate cuts, but risks include currency fluctuations and geopolitical tensions. Analyst sentiment is favorable, emphasizing lower expense ratios and stable dividend income for long-term investors.
Johnson & Johnson (JNJ) trades at $260.88, down 0.36% today, with a bullish technical signal supported by moving averages. The stock shows strong profitability with a net margin of 21.48% and ROE of 25.74%, though valuations like a P/E of 30.14 appear elevated. Recent earnings beat expectations in Q1 and Q2 2026, and the company maintains a 64-year dividend growth streak, with analyst consensus leaning bullish.
Outlook remains positive with a consensus price target of $284.50, offering potential upside, but risks include legal challenges and high debt-to-asset ratio of 24.06% in 2025. Investors benefit from steady dividends and defensive positioning in healthcare, though valuation multiples may limit near-term gains amid economic uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Core MSCI EAFE ETF
IEFA tracks the MSCI EAFE Investable Market Index, offering broad exposure to large, mid, and small-cap stocks in developed markets across Europe, Australasia, and the Far East. It serves as a low-cost core holding for international diversification, excluding the U.S. and Canada.
Read more on IEFA →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
